Michael Bubb, MD
Rheumatology · Gainesville, FLNPI 1770599094
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Genentech USA, Inc. at 32.0% of the total. 2025 is the largest year on record at $6,464, more than ten times the $306 reported in 2019.
Across 78 payments — averaging $193.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- UCB, Inc.$3K
- AstraZeneca$2K
- UCB SA$2K
- Astrazeneca UK Limited$1K
- Biogen$747
- plus $1K from 8 others
Across 225 payments — averaging $14,548 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.4M
- Novartis$740K
- UCB SA$294K
- E.r. Squibb & Sons, L.L.C.$264K
- AstraZeneca$145K
- Bristol Myers Squibb$111K
- plus $336K from 9 others
What the payments were for
- Consulting fees$4,48530%
- Travel & lodging$7,64551%
- Food & beverage$2,88719%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 7 | $4,834 |
| UCB, Inc. | 19 | $3,472 |
| AstraZeneca(2 entities) | 13 | $2,171 |
| UCB SA | 9 | $1,537 |
| Astrazeneca UK Limited | 6 | $1,075 |
| Biogen | 8 | $747 |
| Bristol Myers Squibb | 4 | $266 |
| Sobi, Inc | 2 | $225 |
| E.r. Squibb & Sons, L.L.C. | 3 | $204 |
| Amgen | 2 | $159 |
| Boehringer Ingelheim | 2 | $150 |
| Argenx US, Inc. | 1 | $137 |
| Cardinal Health 110 LLC | 1 | $100 |
| GSK | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GAZYVA$4,572
- SAPHNELO$1,076
- VYVGART HYTRULO$137
- Gamifant$125
- Otezla$116
How this compares
$15,117 in reported general payments places this provider in the 65th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 58 | $484,434 |
| Humira(Cf) PenAdalimumab | 13 | $100,018 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $69,382 |
| Hydroxychloroquine Sulfate | 58 | $2,554 |
| MethotrexateMethotrexate Sodium | 94 | $1,404 |
| Gabapentin | 13 | $216 |
| Prednisone | 36 | $169 |
| Meloxicam | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $3,472 | $69,38212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Gainesville
- Dina HammadGainesville$62K
- Newton EdwardsGainesville$59K
- Ann ChauffeGainesville$49K
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.